The pharmaceutical group Grifols has announced today to the National Securities Market Commission (CNVM) that it has begun negotiations to refinance its debt issues that mature in 2025, one of the points that has focused the concerns of consumers in recent weeks. financial markets and that led rating firms such as Moody's or Fitch to lower their credit rating.
The Catalan firm explained to the CNMV that “it is actively working to issue senior secured debt (“senior secured notes”), whose funds, if successful, will be used to refinance unsecured debt (“senior unsecured notes”) maturing in 2025.”
The company highlights that it continues to make progress in closing the sale of 20% of its Chinese subsidiary Shanghai RAAS to the Haier group, and assured that the proceeds of 1.8 billion dollars (about 1.6 billion euros) will be used to reduce its guaranteed debt . The company, chaired by Thomas Glanzmann, anticipates that this transaction will close in the first half of 2024, as planned.
